Our previous studies indicate that oral treatment with nilotinib, 150 or 300 mg, results in cerebrospinal fluid (CSF) maximum concentration of 2 to 4.7 nM, respectively, in patients with Alzheimer's disease (AD)17 and PD,18, 19, 20 therefore achieving a pharmacologically adequate concentration that would inhibit DDR1. The gene discussed is DDR1; the disease is Alzheimer disease.